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Abstract
Background: Alzheimer's disease (AD) is a neurodegenerative disorder incurring significant social
and economic costs. This study uses a US administrative claims database to evaluate the effect of
AD on direct healthcare costs and utilization, and to identify the most common reasons for AD
patients' emergency room (ER) visits and inpatient admissions.
Methods: Demographically matched cohorts age 65 and over with comprehensive medical and
pharmacy claims from the 2003–2004 MEDSTAT MarketScan® Medicare Supplemental and
Coordination of Benefits (COB) Database were examined: 1) 25,109 individuals with an AD
diagnosis or a filled prescription for an exclusively AD treatment; and 2) 75,327 matched controls.
Illness burden for each person was measured using Diagnostic Cost Groups (DCGs), a
comprehensive morbidity assessment system. Cost distributions and reasons for ER visits and
inpatient admissions in 2004 were compared for both cohorts. Regression was used to quantify the
marginal contribution of AD to health care costs and utilization, and the most common reasons for
ER and inpatient admissions, using DCGs to control for overall illness burden.
Results: Compared with controls, the AD cohort had more co-morbid medical conditions, higher
overall illness burden, and higher but less variable costs ($13,936 s. $10,369; Coefficient of variation
= 181 vs. 324). Significant excess utilization was attributed to AD for inpatient services, pharmacy,
ER visits, and home health care (all p < 0.05). In particular, AD patients were far more likely to be
hospitalized for infections, pneumonia and falls (hip fracture, syncope, collapse).
Conclusion: Patients with AD have significantly more co-morbid medical conditions and higher
healthcare costs and utilization than demographically-matched Medicare beneficiaries. Even after
adjusting for differences in co-morbidity, AD patients incur excess ER visits and inpatient
admissions.
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Alzheimer's disease (AD) is a progressive, irreversible neu-
rodegenerative disorder with high social and economic
costs. Currently, an estimated 5.1 million Americans have
AD, 4.9 million of them over the age of 65 [1]. Alzhe-
imer's disease affects 13% of people over age 65 and
nearly half of those over age 85, accounting for 50 to 70%
of all dementia cases [1]. By 2050, 11.6 to 16 million
Americans may have AD [2]. With the expected increase in
AD cases, medical costs for Medicare beneficiaries with
AD are expected to increase from $91 billion in 2005 to
$160 billion in 2010 [3]. Understanding what contributes
to health care costs and utilization among AD patients
should help health plans develop effective disease man-
agement protocols.
Prior studies [4-16] on costs and utilization associated
with AD in the US have several limitations: 1) most use
data collected prior to 2000 which do not capture current
treatment patterns [4-12,15,16]; 2) several "contaminate"
their definitions of AD cohorts by including diagnosis
codes of non-AD dementias in their claims data analyses
[4-6,8,12]; 3) several present only aggregated total cost
data or omit pharmacy costs [4,9,10,12]; and 4) most rely
on the presence of, at most, a small subset of co-morbidi-
ties to account for the effect of differences in disease bur-
den between cases and controls [4-16].
In addition, no previous research has explored which med-
ical conditions lead to inpatient admissions and emer-
gency room (ER) use for patients with AD or estimated
how AD affects such utilization beyond what would be
expected based on the presence of co-morbidities.
In this study we sought to identify differences in direct
healthcare costs and utilization, and common reasons for
ER visits and inpatient admissions between Medicare ben-
eficiaries with an AD diagnosis and controls, after com-
prehensively adjusting for the presence of other co-
morbidities. Using a large, US administrative claims data-
base, we examined 2004 direct healthcare costs and utili-
zation for individuals aged 65 and above in each cohort
with comprehensive medical (including claims paid by
Medicare) and pharmacy claims. Illness burden was meas-
ured by a comprehensive disease classification and scor-
ing system and used to produce estimates of the marginal
effect of AD on inpatient, ER, pharmacy and other utiliza-
tion and costs. Reasons for ER visits and inpatient admis-
sions were also examined for both AD and control
cohorts, and logistic regression was used to assess the con-
tribution of AD to the most common reasons for ER visits
and hospitalizations controlling for differences in overall
illness burden. Findings from this research may help
healthcare providers and health plans in the US develop
protocols to better manage patients with AD.
Table 1: Demographics, Health Plan Enrollment, and Illness Burden
AD Cohort Control Group
N = 25,109 N = 75,327
Characteristic
Age, Mean (SD)* 80.1 (6.5) 80.1 (6.6)
Age, n (%)
65 – 69 1,529 (6.1) 4,613 (6.1)
70 – 74 3,482 (13.9) 10,330 (13.7)
75 – 79 6,345 (25.6) 19,641 (26.1)
80 – 84 7,326 (29.2) 21,471 (28.5)
85 – 89 4,654 (18.5) 13,428 (17.8)
90+ 1,683 (6.7) 5,844 (7.8)
Female, N (%) 15,473 (61.6) 47,082 (62.5)
Regional distribution, N (%)
Northeast 2,986 (11.9) 10,783 (14.3)
North Central 8,710 (34.7) 25,725 (34.2)
South 9,178 (36.6) 24,028 (31.9)
West 4,185 (16.7) 14,534 (19.3)
Unknown 50 (0.2) 257 (0.3)
Months of health plan enrollment in 2004, Mean (SD) 11.1 (2.51) 11.2 (2.34)
Enrolled all 12 months of 2004, N (%) 21,380 (85.2) 65,949 (87.6)
Number of Comorbidities, Mean (SD)†§ 8.1 (5.5) 6.5 (5.0)
Illness burden score, Mean (SD)‡§ 1.23 (0.80) 1.04 (0.77)
* Age as of 01 Jan 2003 displayed as mean ± standard deviation (SD)
† Diagnostic Cost Group (DCG) Condition Categories (CCs), excluding AD.
‡ Prospective Relative Risk Score (RRS) excluding AD, normalized to 1.0 for the eligible study population.
§ Statistically significant differences between the two groups at p < 0.001.Page 2 of 8
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Study Sample
Data were obtained from the MEDSTAT MarketScan®
Medicare Supplemental and Coordination of Benefits
(COB) Database for 2003 and 2004. These data contain
information about Medicare beneficiaries across the US,
age 65 and older, with employer-sponsored supplemental
insurance including pharmacy benefits. The eligible study
population was comprised of 627,775 individuals with 12
months of enrollment in 2003, at least one month of
enrollment in 2004, and comprehensive inpatient, outpa-
tient, and pharmacy claims. Coverage for skilled nursing
facility care is limited under Medicare, and generally long
term nursing home care is not covered by employer-spon-
sored supplemental insurance. Thus, the cost and utiliza-
tion data presented here do not include care provided in
skilled nursing facilities and nursing homes. Because data
used in this study were purchased from a third party
which had removed identifying information prior to its
release, institutional review board (IRB) and similar
approvals were neither needed nor sought.
From this population we selected 25,109 individuals with
AD and three times as many demographically-matched
controls. The AD cohort contained all patients with at
least one non-laboratory claim with an AD diagnosis
(ICD-9-CM code 331.0) or at least one filled prescription
for an AD-specific medication (tacrine, donepezil, galan-
tamine, rivastigmine, or memintine) in 2003. The control
cohort excluded both those with AD using the above cri-
teria and those with any other form of dementia (ICD-9-
CM codes 290.xx, 294.1x, 294.8x, 331.1x-331.9x, 797.xx)
recorded at any time in either 2003 or 2004. Because a
diagnosis of AD is not always accurate, it is likely that the
AD cohort includes some number of people with demen-
tia arising from other causes, such as vascular dementia.
We used propensity scores to construct the demographi-
cally matched control cohort. First we predicted the prob-
ability of "propensity to have" AD using logistic
regression. Explanatory variables included: 1) age as of
January 1, 2003, 2) age squared, 3) gender, 4) geographic
region, and 5) months of health plan enrollment in 2004.
The data were ranked by the probability of having AD
(from highest to lowest), and then partitioned into twenty
quantiles (with 5% of the population in each). Within
each 5% quantile, eligible individuals were randomly
selected to match each individual in the AD cohort using
a 3 to 1 ratio.
Controlling for Illness Burden
We measured overall illness burden using DxCG, Inc.'s
RiskSmart™ software, which includes the Diagnostic Cost
Groups (DCGs) model. This validated, diagnosis-based
classification system [17] organizes over 15,000 ICD-9-
CM codes into 781 highly homogeneous clinical catego-
ries (DxGroups), which are further clustered into 184
Condition Categories (CCs) that encompass similar med-
ical conditions with similar expected costs [18]. The soft-
ware further organizes the CC information for each
person into a 184-variable vector of "hierarchical CCs"
(HCCs), where the presence of a more serious manifesta-
tion of a disease causes clinically-less-relevant conditions
to be "zeroed out." For example, "chronic obstructive lung
disease" dominates "cold" [18].
Table 2: 2004 Annualized Health Care Costs and Utilization by Type of Service
AD Controls Contribution of AD†
% of Cohort 
Using
Mean Visit 
Days
Mean Cost $ 
(CV)*
% of Cohort 
Using
Mean Visit 
Days
Mean Cost $ 
(CV)*
Visit Days† Cost $ †
Inpatient 30 3.38 5,094 (419) 20 1.93 4,014 (753) 1.14‡ 671‡
Pharmacy 94 -- 4,056 (77) 85 -- 2,169 (174) -- 1,711‡
Hospital 
outpatient
61 2.61 1,252 (298) 58 2.51 1,412 (384) -0.30‡ -366‡
Physician office 79 8.46 1,100 (237) 81 9.97 1,508 (270) -2.86‡ -648‡
Emergency 
room
41 1.04 335 (280) 27 0.64 196 (530) 0.28‡ 107‡
Home health 7 0.24 32 (1,001) 4 0.15 27 (3,191) 0.05‡ 0.37
Other 56 -- 2,068 (353) 37 -- 1,043 (571) -- 789‡
Total 
Utilization
97 -- 13,936 (181) 91 -- 10,369 (324) -- 2,307‡
* CV = Coefficient of Variation = 100*SD/Mean
† Coefficient of the AD indicator from the weighted least square regression for annualized costs, or utilization within each setting controlling for 
overall illness burden (RRS excluding AD and RRS squared).
‡ Statistically significant effects attributed to AD at p < 0.05.Page 3 of 8
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population using HCCs from the 2003 diagnoses, age,
and sex. The CC for AD was excluded from the estimation
so that the AD and control cohorts would have compara-
ble predicted costs after controlling for demographics and
all co-morbidities other than AD in 2003.
Predicted costs were then normalized (multiplied by the
appropriate constant) to create prospective relative risk
scores (RRSs) that average 1.00 in the eligible study pop-
ulation.
Analyses
Demographics such as age, gender, and region were used
to characterize the AD cohort and controls. We also calcu-
lated mean duration of health plan enrollment in 2004,
the number of unique co-morbid conditions, and the RRS
for non-AD illness burden.
Health care costs and utilization were calculated for 2004
by place of service, including physician office visits, out-
patient hospital services, ER visits, inpatient services,
home health care, and pharmacy. All costs included
deductibles, copayments, coinsurance, and coordination-
of-benefits payments. For partial year enrollees, utiliza-
tion and expenditures were annualized (actual totals
divided by percentage of year enrolled). Total health care
costs were compared using the mean, computed t-tests of
the differences in means, standard deviation (SD), cost
dispersion as measured by the coefficient of variation
(CV) and cost distribution by place of service. Health care
utilization was evaluated by examining percentages of
users, the mean cost per member per year and, where
applicable, the number of encounters (visits) per member
per year.
Regression was used to estimate AD's independent effect
on overall costs and utilization. Specifically, Weighted
Least Squares (WLS) regressions were used to assess the
marginal contribution of AD to 2004 costs and health care
utilization, weighted by the fraction of time enrolled in
2004. Explanatory variables included: 1) an indicator var-
iable (0/1) identifying individuals in the AD cohort; 2)
the RRS, as a measure of total non-AD illness burden; and
3) RRS squared. The coefficient associated with the AD
indicator measures the extent to which AD contributes to
excess healthcare costs or utilization after controlling for
differences in overall illness burden.
The most common reasons for inpatient admissions and
for ER visits were identified by mapping the first diagnosis
from each claim into a DxGroup category. We also com-
pared the prevalence per 10,000 persons of ER visits and
inpatient admissions between the AD cohort and con-
trols. We assessed the marginal contribution of AD to ER
visits and inpatient admissions controlling for difference
in overall illness burden via logistic regressions using the
same predictors in WLS regressions as noted above.
All analyses were performed using SAS software (version
9.1, SAS, Cary, NC).
Table 3: Top 10 Reasons for ER Visits by Cohort
AD Control Odds Ratio*
Rate per 10,000 (Rank within cohort)†
Contusion/superficial injury 679 (1) 270 (2) 2.23‡
Chest pain 480 (2) 353 (1) 1.16‡
Syncope and collapse 333 (3) 115 (10) 2.64‡
Open wound except eye and lower arm 316 (4) 115 (11) 2.54‡
Cystitis, other urinary tract infections 306 (5) 103 (13) 2.69‡
Other general symptoms 300 (6) 130 (7) 2.07‡
Other and unspecified pneumonia 288 (7) 145 (5) 1.74‡
Abdominal/pelvis symptoms 279 (8) 219 (3) 1.10
Stupor/altered consciousness/trans global amnesia/febrile convulsions 264 (9) 41 (37) 5.85‡
Disorders of fluid/electrolyte/acid-base balance, e.g., dehydration 252 (10) 94 (16) 2.36‡
Heart failure 192 (14) 181 (4) 0.87‡
Stomach/intestinal disorders/symptoms, except obstruction, ulcer, and hemorrhage 223 (12) 136 (6) 1.43‡
Arthropathy/joint disorders, derangements, joint pain/stiffness, excluding gout 193 (13) 122 (8) 1.49‡
Nonspecific backache and other back/neck pain/disorders 141 (20) 121 (9) 1.05
Any ER visit 10,413 5,733 1.74‡
* Odds ratio of the AD indicator from the logistic regression predicting any ER visit controlling for overall illness burden (RRS excluding AD and 
RRS squared).
† 10,000 times the number of ER visits divided by number of individuals in the cohort. Bold text designates reason in the top ten.
‡ Statistically significant AD effect at p < 0.05.Page 4 of 8
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As constructed, the control group did not differ from the
AD cohort with respect to age, sex, regional distribution,
or mean length of eligibility in 2004 (Table 1). However,
the AD cohort had more co-morbidities (mean of 8.1 CCs
vs. 6.5, p < 0.001), and a greater burden of non-AD illness
(mean RRS of 1.23 vs. 1.04, p < 0.001).
Annualized costs and utilization by place of service are
summarized in Table 2. The vast majority of AD patients
(97%) and controls (91%) used some healthcare services
in 2004. Rates of ER visits (41% vs. 27%), inpatient hos-
pital stays (30% vs. 20%), and home health care (7% vs.
4%) were about 50% higher for AD patients than for con-
trols. Controlling for overall illness burden, the excess uti-
lization attributed to AD for inpatient services, ER visits,
and home health care were all significant (p < 0.05). How-
ever, the AD cohort used fewer physician office visits and
outpatient hospital services (both p < 0.05). Differences
in costs attributed to AD were statistically significant (p <
0.05) for all categories except home health care. Spending
in the AD cohort was higher for all but two categories of
services (outpatient services and office visits) compared to
controls, but AD spending was always less variable (coef-
ficient of variation (CV) was lower). Excess pharmacy
costs associated with AD were $1,711, more than twice
that of any other expense category (p < 0.05).
The 10 most common reasons for ER visits among indi-
viduals belonging to the AD or control cohorts, and their
rates and comparative prevalence, are shown in Table 3.
The AD and control cohorts shared 6 of their 10 most
common reasons, and their top two reasons (contusion/
superficial injury and chest pain) were the same. The AD
cohort had higher raw ER use rates than controls for all 14
reasons listed, and significantly higher risk-adjusted use
rates for 11 of them with odds ratios (ORs) ranging as
high as 5.85 for stupors and other states of altered con-
sciousness. Only one of the 14 reasons shown (heart fail-
ure) had risk-adjusted ER use rate lower for AD patients
than for controls (OR = 0.87, p < 0.05). The odds of an
individual in the AD cohort having an ER visit for any rea-
son was 74% greater than for controls.
Analogous to the previous table, Table 4 compares utiliza-
tion for the top 10 most common reasons for inpatient
admission for each cohort. Only 3 of the top reasons (hip
fracture, other and unspecified pneumonia, and cystitis/
other urinary tract infections) were shared. Even after con-
trolling for illness burden, patients in the AD cohort were
more likely to be hospitalized for most of the reasons
listed, including pneumonia, infections, syncope and hip
fracture. However, AD patients were less likely to be
admitted to the hospital due to heart failure or coronary
atherosclerosis and other coronary ischemic heart disease
(all p < 0.05) compared with those in the control cohort.
Table 4: Top 10 Reasons for Inpatient Admission by Cohort
AD Control Odds Ratio*
Rate per 10,000 (Rank within cohort)†
Other and unspecified pneumonia 229 (1) 133 (2) 1.50‡
Femoral (hip) fracture 209 (2) 88 (4) 2.32‡
Cystitis, other urinary tract infections 161 (3) 42 (13) 3.46‡
Heart failure 150 (4) 158 (1) 0.78‡
Cerebral degeneration/Alzheimer's disease 142 (5) - infinite
Disorders of fluid/electrolyte/acid-base balance, e.g., dehydration 118 (6) 49 (11) 2.16‡
Septicemia (blood poisoning)/shock 118 (7) 14 (39) 2.77‡
Syncope and collapse 100 (8) 33 (30) 2.85‡
Aspiration pneumonia 100 (9) 18 (16) 5.36‡
Pre-cerebral or cerebral arterial occlusion with infarction 84 (10) 48 (12) 1.74‡
Coronary atherosclerosis and other chronic ischemic heart disease (CAD) 70 (13) 111 (3) 0.53‡
Acute myocardial infarction, initial episode of care 83 (11) 81 (5) 0.92
Atrial arrhythmia 56 (16) 62 (6) 0.83
Osteoarthritis of lower leg (knee) 27 (29) 62 (7) 0.39‡
Emphysema/chronic bronchitis, 18+ 65 (14) 55 (8) 1.02
Gastrointestinal hemorrhage, except peptic ulcer and anal/rectal 78 (12) 55 (9) 1.22‡
Chest pain 54 (17) 50 (10) 0.94
Any inpatient admission 3,796 2,408 1.55‡
* Odds ratio of the AD indicator from the logistic regression predicting any inpatient admission controlling for overall illness burden (RRS excluding 
AD and RRS squared).
†10,000 times the number of inpatient admissions divided by number of individuals in the cohort. Bold text designates reason in the top ten.
‡ Statistically significant AD effect at p < 0.05.Page 5 of 8
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likely in the AD cohort was for osteoarthritis of lower leg
(knee), typically related to knee surgery. The odds for an
inpatient admission were 55% greater for AD patients
than for controls.
Discussion
Our study is the first to examine the most common med-
ical conditions among AD patients that lead to inpatient
admissions and ER use, and to contrast AD patients' co-
morbid diseases and utilization with those of a demo-
graphically-matched control group. Earlier studies
accounted for just a few co-morbidities in seeking to iso-
late AD's influence on costs and utilization. Using a com-
prehensive co-morbidity assessment for AD patients and a
demographically-matched control group, we have
achieved credible estimates of the independent effect of
AD on healthcare costs and utilization. Individuals in the
AD cohort had more unique co-morbid medical condi-
tions and higher overall illness burden than those in the
control cohort. Use of services was greater for AD patients,
with far more inpatient, ER, and home health encounters.
Mean excess cost attributed to AD, even after controlling
for the greater overall burden of illness, was $2,307.
The AD cohort had considerably higher pharmacy costs
[7,8,13,14] and total health care costs [4,7,8,11-13] than
seen in previous studies. The findings establish the need
to better understand pharmacy management practices for
AD patients given pharmacy's large contribution to their
elevated costs. Compared with demographically-matched
controls, AD patients had significantly higher but less var-
iable costs. So although patients with AD were costly, their
costs were more predictable than those in the control
cohort.
In our study, AD patients on average had longer hospital
days and more visits than controls for all utilization cate-
gories except physician office visits. Overall prevalence
rates for ER visits and inpatient admissions were signifi-
cantly higher for AD patients. Closely managing hospital-
ization as well as ER visits may have significant impact on
health care resource use in AD.
Alzheimer's disease complicates the management of an
elderly population with significant co-morbid disease.
Patient non-cooperation, inability to communicate, less
frequent office visits, and caregiver burden may all con-
tribute to "simple" medical problems escalating into hos-
pital admissions or ER visits for reasons such as
pneumonia, dehydration and septicemia. Dehydration,
for example, may precipitate other medical problems,
including cystitis, electrolyte imbalances, contusions, and
hip fractures. However, it is unclear if dehydration requir-
ing ER care or hospitalization is really more common in
AD patients; an alternative explanation is that "dehydra-
tion" is used to code admissions requested by stressed car-
egivers in the absence of clear clinical symptoms.
Alzheimer's patients have many co-morbid medical prob-
lems and use multiple medications [14,19,20]; they may
be prone to harm themselves [13]. The use of multiple
medications raises the risk of adverse drug reactions and
drug-drug interactions, and complicates medication com-
pliance [21]. Polypharmacy, especially in the elderly pop-
ulation, is associated with adverse drug reactions [22-24],
which occur in 5–10% of hospital inpatient admissions
and increase hospital stays and costs [25]. All these fac-
tors, especially when combined with impaired cognition,
could contribute to the observed increase in hospitaliza-
tions for hip fracture and syncope for AD patients. These
findings suggest opportunities for improvement through
case management to address AD patients' co-morbidities,
specifically through medication reviews.
Differences in disease prevalence also lead to higher rates
of hospitalization (most prominently, hospitalizations
for AD itself). However, differences in co-morbidities do
not explain AD patients' lower use of hospitalizations for
heart problems since heart problems were similarly com-
mon in the two cohorts. This may be due to reduced
awareness of (non-obvious) heart problems or because
heart problems are treated less aggressively in AD patients.
For example, ER visits for "chest pain" were more com-
mon in patients with AD compared to controls, although
hospital admissions were less common.
Our study has several limitations. First, we examined
Medicare-eligible individuals with employer-sponsored
supplemental insurance, mostly from large companies
whose active or former employees do not necessarily rep-
resent the general population of Medicare beneficiaries.
This may contribute to the relatively low (4%) AD preva-
lence in this elderly cohort. Second, AD patients in our
study were identified via diagnoses in administrative
claims. Thus, some non-AD patients may be in our AD
cohort (due to a false AD diagnosis) while some people
with AD will be excluded (due to either a lack of any AD
diagnosis or to misclassification, for example, as vascular
dementia). Thirdly, the costs provided in our data do not
capture care provided in skilled nursing facilities or nurs-
ing homes, therefore our analysis may underestimate the
total direct healthcare costs of AD. Fourthly, our claims
data do not have information on the duration or severity
of AD, which is significantly related to healthcare cost and
utilization [7,26]. Although we controlled for differences
in overall co-morbidities in our analysis, we could not
control for disease severity. Fifthly, our data do not
include information on living situation (e.g., home versus
institution), which may also affect healthcare costs andPage 6 of 8
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the indirect costs of AD are substantial [1], this study
focused only on direct healthcare costs.
Conclusion
Compared to a demographically-matched control cohort,
AD patients had significantly more co-morbid medical
conditions and higher overall illness burden. Even after
adjusting for differences in overall illness burden, people
with AD incurred markedly more health care costs than
their age-matched peers. The greater predictability of AD
spending and more frequent, more costly, and different
use of hospitals, suggests opportunities for improvement.
Significantly increased financial exposure to AD with the
expansion of prescription drug coverage under Medicare
increases the pressure on health plans to develop more
effective management protocols for AD patients.
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